Skip to content
Menu

Avalyn Pharma Inc. AVLN

Full chart Compare
Set alert

Price alert · AVLN

All alert types
28.70 USD +1.01 (+3.65%)

Regular-session close

28.14 -0.56 -1.95%

After hours · Nov 19, 4:00 PM ET

27.01 Day range 28.90
22.24 52-week range 40.17
YTD
-2.68%
1 year
-2.68%

 

No chart data for this range yet.
Market cap
1.28B
EPS (ttm)
-3.96
Shares out
44.52M
Forward P/E
-11.12
YTD return
-2.68%
1-year return
-2.68%
50-day average
28.15
200-day average
29.88
Enterprise value
922.28M
Volume
437.29K
Avg volume
352.09K
Open
27.86
Previous close
27.69
Day's range
27.01 – 28.90
52-week range
22.24 – 40.17
Analysts
Strong Buy
Price target
61.00 (+112.5%)
Earnings date
Feb 11, 2027

Key statistics

Price / book
3.44
Total cash
327.46M
Total debt
16.93M
Short % of float
5.19%

Fundamental scorecard

3 of 25 checks passed on AVLN’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth No data
  • Profitability No data
  • Financial health 3 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
AVLN Revenue — quarterly 0
AVLN Net income — quarterly -29.66M
AVLN EPS — quarterly -0.67

Earnings

AVLN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 11, 2027Dec 30, 2026-0.70———
Nov 12, 2026Sep 30, 2026-0.67333-0.670.00+0.49%
Aug 12, 2026Jun 30, 2026-0.77667-0.98-0.20-26.18%
Jun 3, 2026Mar 31, 2026-5.98-21.83-15.85-265.25%

Upgrades / downgrades

AVLN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 2, 2026Raymond Jamesinit—Outperform
Aug 13, 2026Morgan StanleymainOverweightOverweight
May 26, 2026Evercore ISI Groupinit—Outperform
May 26, 2026Guggenheiminit—Buy
May 26, 2026Morgan Stanleyinit—Overweight

About Avalyn Pharma Inc.

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on AVLN — it syncs with the Stock Master app.

Insider holders

AVLN insider holders
InsiderRelationLatest transactionDateShares held
CARROLL JILLDirectorPurchaseApr 30, 20260
FMR LLCBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityApr 30, 20260
NOVO HOLDINGS A/SBeneficial Owner of more than 10% of a Class of SecurityPurchaseApr 30, 20263,883,290
SR ONE CAPITAL MANAGEMENT, LLCBeneficial Owner of more than 10% of a Class of SecurityPurchaseApr 30, 20260
WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN IIBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityApr 30, 20261,275,490

Institution ownership

AVLN institution ownership
Holder% heldSharesValueReported
FMR, LLC13.89%6,185,994177.54MSep 29, 2026
Novo Holdings A/S7.75%3,449,19198.99MSep 29, 2026
SR One Capital Management, LP7.43%3,308,64994.96MSep 29, 2026
Perceptive Advisors Llc6.01%2,675,29676.78MSep 29, 2026
Montanova Capital LLC5.62%2,503,10971.84MSep 29, 2026
NVP Associates, LLC5.10%2,268,40465.10MSep 29, 2026

Fund ownership

AVLN fund ownership
Holder% heldSharesValueReported
Fidelity Securities Fund-Fidelity Small Cap Growth Fund2.77%1,231,62035.35MAug 30, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund1.41%627,19018.00MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.20%534,44015.34MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.05%466,56513.39MSep 29, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.0.93%415,61011.93MJun 29, 2026
T. Rowe Price Health Sciences Fund, Inc.0.89%396,06911.37MJun 29, 2026